EUROAPI progressively restarted prostaglandin production at its Budapest site on January 19.

As communicated to the market in its press release of December 7, 2022, EUROAPI identified certain Good Manufacturing Practices deficiencies related to production documentation during an internal assessment and decided, out of an abundance of caution, to proactively and temporarily suspend prostaglandin activities at its Budapest site. The Group has built and successfully implemented a comprehensive remediation plan, allowing to progressively restart prostaglandin production in January. As the restart is progressive in nature by design, EUROAPI expects the majority of prostaglandin production to be back online by Mid-April 2023.

As anticipated, no other activities at the Budapest site were impacted, including Contract Development and Manufacturing Organization (CDMO) activities.

As transparency and quality are the Group’s highest priorities, EUROAPI has been keeping the relevant health authorities as well as its clients and partners informed.